Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery hosts Kinase 2016: Next Generation Inhibitors

Sygnature Discovery sponsored and hosted the Kinase 2016: Next Generation Inhibitors symposium at BioCity Nottingham this year.  This is the first time the conference has been held in Nottingham and it was a sell-out.

Over 120 delegates attended the two-day symposium which included exceptional keynote speakers, an exhibition and poster presentations.

Perturbation of cell signalling through inhibition of kinase enzymes has delivered nearly thirty approved medicines to date. In its seventh year, the Kinase symposium on kinase inhibitor design featured several themes including new approaches and technologies to modulate and measure kinase function; as well as diverse medicinal chemistry case studies.

Delegates also had the opportunity to take part in a poster session and networking activities.

Organised by the SCI and the Royal Society of Chemistry in partnership with Sygnature Discovery, the symposium provided transferable lessons and insight into cutting-edge discovery in kinase research.

Latest News

View All

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.